Sumitomo Pharma America 401(k) match, vesting and fees

Plan year 2025 filingMy 401(k) Plan · Plan 001 · EIN 22-2536587Updated Oct 2026

What Sumitomo Pharma America's 401(k) plan says about matching contributions

The match terms have not been published from this plan's filing yet.
The plan year 2025 filing reports $15.4M in employer contributions, about $5,880 per participant. That total includes any match and profit-sharing; it is not a match formula. Plan year 2025 Form 5500 ↗
$262,647
Average account balance
2,672
Participants (end of year)
$687M
Plan assets (end of year)
0.03%
Admin expenses ÷ assets

Plan features

Match, vesting and enrollment details have not been published from this plan's audit report yet. The figures below come from the structured filing.

RecordkeeperFidelity Investments InstitutionalSchedule C ↗
Independent auditorCaron & Bletzer PLLC (unmodified opinion, limited scope)Schedule H ↗
Plan type and status401(k) · ActiveForm 5500 ↗

How the plan compares

Plan year 2025 medians for 434 defined-contribution plans in manufacturing with 1,000 to 4,999 participants.

Sumitomo Pharma America: employer contribution per participant$5,880
Peer median$2,591
Sumitomo Pharma America: average balance$262,647
Peer median$102,504
Sumitomo Pharma America: admin expenses ÷ assets0.03%
Peer median0.11%

Admin expenses are the plan's reported administrative expenses divided by its assets; they do not include fund expense ratios.

Plan history

Plan assets went from $635M at the end of plan year 2021 to $687M at the end of plan year 2025.

$635M2021$647M2023$634M2024$687M2025
End-of-year figures from each plan year's Form 5500 filing for the Sumitomo Pharma America plan.
Plan yearParticipantsAssetsEmployer contributionsPer participantAdmin expense ratioMatch formulaFiling
20252,672$687M$15.4M$5,8800.03%Not publishedForm 5500 ↗
20242,832$634M$16M$5,7880.03%Not publishedForm 5500 ↗
20233,318$647M$15.9M$4,9950.04%Not publishedForm 5500 ↗
20212,481$635M$16.7M$6,9750.04%Not publishedForm 5500 ↗

Other Sumitomo Pharma America plans (1)

Each plan files its own Form 5500. Figures are from each plan's latest filing.

The Savings and Investment Plan for Puerto Rican Employees of Sumitomo Pharma America, Inc.

Plan 002 · EIN 22-2536587 · plan year 2025 filing
$365,854
Average account balance
4
Participants (end of year)
$1.1M
Plan assets (end of year)
1.61%
Admin expenses ÷ assets

Plan features

Match, vesting and enrollment details have not been published from this plan's audit report yet. The figures below come from the structured filing.

Plan type and status401(k) · ActiveForm 5500 ↗

Common questions

Does Sumitomo Pharma America match 401(k) contributions?

The match terms for the My 401(k) Plan have not been published from its filing yet. The plan year 2025 filing reports $15.4M in employer contributions, about $5,880 per participant. That total includes any match and profit-sharing; it is not a match formula.

When is the Sumitomo Pharma America 401(k) match vested?

The vesting schedule for the My 401(k) Plan is not in the data published so far. Your Summary Plan Description states it.

Who manages the Sumitomo Pharma America 401(k)?

The recordkeeper listed on Schedule C of the plan year 2025 filing is Fidelity Investments Institutional. The plan administrator is Sumitomo Pharma America, Inc..

I left Sumitomo Pharma America. How do I find my old 401(k)?

Your account stays in the plan until you move it. Contact the plan administrator (Sumitomo Pharma America, Inc., (501) 481-6700) or the recordkeeper, Fidelity Investments Institutional. The Sumitomo Pharma America old 401(k) page lists the contacts from every plan filing. Find an old Sumitomo Pharma America 401(k)

Data from the public Form 5500 annual reports Sumitomo Pharma America filed with the U.S. Department of Labor (plan years 2021 and 2022 and 2023 and 2024 and 2025) and, where noted, the attached independent auditor's report. Plan terms may have changed since the filing; check your current Summary Plan Description. PlanFacts is not affiliated with Sumitomo Pharma America. Not financial advice. Report a correction · Methodology